2'-Fluoro-2',3'-dideoxyarabinosyladenine (F-ddA): Activity against drug-resistant human immunodeficiency virus strains and clades A-E

Antiviral Chemistry and Chemotherapy

Volumn 8, Issue 2, 1997, Pages 107-111

  Driscoll, J S ^a   Mayers, D L ^b   Bader, J P ^a   Weislow, O S ^c   Johns, D G ^a   Buckheit Jr , R W ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c SRA Technologies Inc   (United States)

^d SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

clade; cross resistance; F ddA; HIV

Indexed keywords

2',3' DIDEOXYADENOSINE; DIDANOSINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; VIRUS STRAIN;

EID: 0031057088     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029700800204     Document Type: Article

References (28)

1. Boyle MJ, Flanigan ME, Ford H, Baseler M, Adelsberger J, Davey RT & Lane HC (1995) The Hu-HIV/PBL-SCID mouse: a modified Hu-PBL-SCID model for the study of HIV pathogenesis and therapy. Journal of Immunology 154: 6212-6223.
2. D'Aquila RT (1994) HIV-1 drug resistance. Clinics in Laboratory Medicine 14: 393-422.
3. De Clercq E (1992) HIV inhibitors targeted at the reverse transcriptase. AIDS Research and Human Retroviruses 8: 119-133.
4. De Clercq E (1994) HIV resistance to reverse transcriptase inhibitors. Biochemical Pharmacology 47: 155-169.
5. De Clercq E (1995) Antiviral therapy for human immunodeficiency virus infections. Clinical Microbiology Reviews 8: 200-239.
6. Driscoll JS, Siddiqui MA, Ford H, Kelley JA, Roth JS, Mitsuya H, Tanaka M & Marquez VE (1996) Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 3. 6-Amino prodrugs of 2′-β-fluoro-2′,3′-dideoxyinosine. Journal of Medicinal Chemistry 39: 1619-1625.
7. Erice A & Balfour HH (1994) Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review. Clinical Infectious Diseases 18: 149-156.
8. Gao W-Y, Shirasaka T, Johns DG, Broder S & Mitsuya H (1993) Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. Journal of Clinical Investigation 91: 2326-2333.
9. Gao W-Y, Agbaria R, Driscoll JS & Mitsuya H (1994) Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. Journal of Biological Chemistry 269: 12633-12638.
10. Halliday SH, Lackman-Smith C, Decker WD, Bader JP, Rice W, Clanton DJ & Buckheit RW (1996) Inhibition of HIV replication by the sulfonated dye, resobene. Antiviral Research (in press).
11. Hitchcock MJM, Woods K, De Boeck K & Ho H-T (1990) Biochemical pharmacology of 2′-fluoro-2′,3′-dideoxyarabinosyladenine, an inhibitor of HIV with improved metabolic and chemical stability over 2′,3′-dideoxyadenosine. Antiviral Chemistry and Chemotherapy 1: 319-327.
12. Japour AJ, Mayers DL, Johnson VA, Kuritzkes DR, Beckett LA, Arduino J-M, Lane J, Black RA, Reichelderfer PF, D'Aquila RT & Crumpacker CS (1993) Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrobial Agents and Chemotherapy 37: 1095-1101.
13. Kilby JM & Saag MS (1994) Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection? Infectious Agents and Disease 3: 313-323.
14. Larder BA, Darby G & Richman DD (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 1731-1734.
15. Larder BA, Chesebro B & Richman DD (1990) Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrobial Agents and Chemotherapy 34: 436-441.
16. Marquez VE, Tseng CK-H, Kelley JA, Mitsuya H, Broder S, Roth JS & Driscoll JS (1987) 2′,3′-Dideoxy-2′-fluoro-ara-A. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV). Biochemical Pharmacology 36: 2719-2722.
17. Marquez VE, Tseng CK-H, Mitsuya H, Aoki S, Kelley JA, Ford H, Roth JS, Broder S, Johns DG & Driscoll JS (1990) Acid-stable 2′-fluoro purine dideoxynucleosides as active agents against HIV. Journal of Medicinal Chemistry 33: 978-985.
18. Masood R, Ahluwalia GS, Cooney DA, Fridland A, Marquez VE, Driscoll JS, Hao Z, Mitsuya H, Perno C-F, Broder S & Johns DG (1990) 2′-Fluoro-2′,3′-dideoxyarabinosyladenine: a metabolically stable analogue of the antiretroviral agent 2′,3′-dideoxyadenosine. Molecular Pharmacology 37: 590-596.
19. Mayers DL (1996) Resistance and cross-resistance to nucleoside reverse transcriptase inhibitors. HIV: Advances in Research and Therapy 6: 15-21.
20. Mayers DL, Japour AJ, Arduino J-M, Hammer SM, Reichman R, Wagner KF, Chung R, Lane J, Roberts CR, Winslow D, Burke D & the RV43 Study Group (1994) Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. Antimicrobial Agents and Chemotherapy 38: 307-314.
21. Mellors JW, Larder BA & Schinazi RR (1995) Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. International Antiviral News 3: 8-13.
22. Moore JP, Cao Y, Leu J, Qin L, Korber B & Ho DD (1996) Interand intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp 120 antigenic serotypes. Journal of Virology 70: 427-444.
23. Otto MJ, Garber S, Winslow DL, Reid CD, Aldrich P, Jadhav PK, Patterson CE, Hodge CN & Cheng Y-SE (1993) In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proceedings of the National Academy of Sciences, USA 90: 7543-7547.
24. Richman DD (1993) Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrobial Agents and Chemotherapy 37: 1207-1213.
25. Richman DD (1994) Resistance, drug failure, and disease progression. AIDS Research and Human Retroviruses 10: 901-905.
26. Ruxrungtham K, Boone E, Ford H, Driscoll JS, Davey RT & Lane HC (1996) Potent activity of 2′-β-fluoro-2′,3′-dideoxyadenosine against human immunodeficiency virus type 1 infection in huPBL-SCID mice. Antimicrobial Agents and Chemotherapy 40: 2369-2374.
27. Smith M, Salomon H & Wainberg MA (1994) Development and significance of nucleoside drug resistance in infection caused by the human immunodeficiency virus type 1. Clinical and Investigative Medicine 17: 226-243.
28. Weislow OS, Kiser R, Fine DL, Bader J, Shoemaker RH & Boyd MR (1990) New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. Journal of the National Cancer Institute 81: 577-586.